Skill Guide

Technical specification writing for AI-powered clinical features

The creation of comprehensive, regulated documentation that defines the technical requirements, AI model specifications, data pipelines, and safety/performance criteria for software features intended to diagnose, treat, or manage patient conditions.

This skill is critical for ensuring AI clinical features are developed with regulatory compliance (FDA, CE), patient safety, and clinical validity from the outset, directly reducing market time and legal risk. It bridges the gap between clinical needs and engineering execution, ensuring features are both medically sound and technically feasible.

1 Careers

1 Categories

9.1 Avg Demand

15% Avg AI Risk

How to Learn Technical specification writing for AI-powered clinical features

Focus on: 1) Understanding core AI/ML concepts (model types, training/validation/testing splits, metrics like AUC-ROC, sensitivity/specificity). 2) Studying foundational regulatory standards (FDA's SaMD framework, ISO 13485, IEC 62304 for software lifecycle). 3) Mastering the structure of a requirements specification document (SRS) as per IEEE 830.

Transition by writing specs for non-critical AI features (e.g., patient scheduling optimization). Key focus: Defining verifiable requirements (e.g., 'Model shall achieve >=95% sensitivity on dataset X'). Common mistake: Writing vague requirements like 'AI should be accurate.' Learn to use traceability matrices linking requirements to design, tests, and risk controls.

Mastery involves architecting specs for Class II/III AI-based SaMD, integrating real-world performance monitoring plans, and defining algorithms for bias detection and continuous learning. Align specifications with Quality Management System (QMS) processes and lead cross-functional reviews with clinical, legal, and data science teams.

Practice Projects

Beginner

Project

Draft a Spec for a Clinical Decision Support (CDS) Alert

Scenario

Write a technical specification for an AI feature that alerts physicians to a potential sepsis risk based on EHR vitals and lab data.

How to Execute

1. Define the clinical use case and user (attending physician). 2. Specify input data sources (HR, BP, WBC) and their expected formats/refresh rates. 3. Define the model output (risk score 0-1, alert threshold). 4. Draft verifiable performance requirements (e.g., >=85% sensitivity, <5% false positive rate on historical data) and safety mitigations for false negatives.

Intermediate

Case Study/Exercise

Navigate a Regulatory Pathway Conflict

Scenario

Your spec for an AI-powered diabetic retinopathy screening tool uses a novel deep learning architecture that doesn't fit neatly into existing FDA predicate devices. The regulatory team insists on a De Novo pathway, but engineering argues it's too slow.

How to Execute

1. Analyze the technical novelty against the FDA's SaMD risk categorization (state of healthcare situation, significance of information provided). 2. Draft a 'Predetermination Change Control Plan' as part of the spec for the intended modifications of the AI/ML algorithm. 3. Define specific pre-specified performance thresholds in the spec that, if exceeded, would trigger a regulatory re-submission. 4. Lead a cross-functional decision meeting presenting this structured specification as a compromise path.

Advanced

Project

Architect a Spec for a Continuously Learning SaMD

Scenario

You are the lead technical writer for an AI-based ECG arrhythmia detector that is designed to improve its performance over time with incoming hospital data. This requires a 'Predetermined Change Control Plan' for the FDA.

How to Execute

1. Define the 'locked' vs. 'adaptive' algorithm parameters in the spec. 2. Specify the data pipeline for continuous monitoring of real-world performance (RWP), including metrics for data drift and model drift. 3. Architect the algorithm change protocol (ACP): define the re-training triggers, validation benchmarks, and human-in-the-loop review gates. 4. Write the validation protocol for the re-training cycle as an annex to the main spec, ensuring each change remains within the pre-specified performance envelope.

Tools & Frameworks

Regulatory & Standards Frameworks

FDA Pre-Submission ProgramISO 14971 (Risk Management for Medical Devices)IEC 62304 (Medical Device Software Lifecycle)FDA's AI/ML-Based SaMD Action Plan

These are non-negotiable structures for spec writing. ISO 14971 guides the risk analysis section. IEC 62304 dictates software development lifecycle documentation. The FDA frameworks define the content and structure for regulatory submission-ready specifications.

Technical & Documentation Tools

Jira/Azure DevOps (for traceability)Confluence/SharePoint (for living documents)Pandas/Scikit-learn (for defining dataset/validation specifications)MLflow/Kubeflow (for specifying ML pipeline requirements)

Use Jira to maintain a requirements traceability matrix from spec requirement to code commit and test case. Use data science tools to precisely specify dataset characteristics, preprocessing steps, and validation splits within the document.

Interview Questions

Answer Strategy

Use the SMART framework (Specific, Measurable, Achievable, Relevant, Time-bound). Emphasize translating clinical outcomes into technical metrics and regulatory context. Sample answer: 'I would define primary success criteria as model performance metrics: AUROC >= 0.75 and sensitivity >= 70% at a clinically determined specificity threshold, validated on a hold-out set from our target population. In the spec, this would be a verifiable requirement tied to a predefined validation protocol. Secondary criteria would include calibration metrics and fairness assessments across demographic subgroups, referencing ISO 14971 for risk controls if thresholds are not met.'

Answer Strategy

Tests negotiation, risk management, and technical translation skills. The core competency is translating an absolute clinical desire into a risk-based, verifiable technical requirement. Sample answer: 'I would facilitate a meeting to align on risk. We would specify the requirement not as 'zero misses' but as a 'false negative rate of <=X%', determined by a clinical risk-benefit analysis. The spec would then mandate specific, layered risk controls: 1) A high-sensitivity model threshold, 2) A failsafe system (e.g., mandatory physician override and audit trail for all negative predictions), and 3) A post-market surveillance plan to monitor real-world false negatives.'